LV10956B - Use of dimethylbenzofurans and dimethylbenzopyrans as 5-ht3 antagonists - Google Patents

Use of dimethylbenzofurans and dimethylbenzopyrans as 5-ht3 antagonists Download PDF

Info

Publication number
LV10956B
LV10956B LVP-95-184A LV950184A LV10956B LV 10956 B LV10956 B LV 10956B LV 950184 A LV950184 A LV 950184A LV 10956 B LV10956 B LV 10956B
Authority
LV
Latvia
Prior art keywords
formula
methoxy
enantiomers
amino
cis
Prior art date
Application number
LVP-95-184A
Other languages
English (en)
Latvian (lv)
Other versions
LV10956A (lv
Inventor
Daele Georges Henri Paul Van
Jean-Paul Rene Marie Andre Bosmans
Laerhoven Willy Joannes Carolus Van
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of LV10956A publication Critical patent/LV10956A/xx
Publication of LV10956B publication Critical patent/LV10956B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Addiction (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Dental Preparations (AREA)
LVP-95-184A 1992-11-20 1995-06-20 Use of dimethylbenzofurans and dimethylbenzopyrans as 5-ht3 antagonists LV10956B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97901392A 1992-11-20 1992-11-20
PCT/EP1993/003206 WO1994012494A1 (en) 1992-11-20 1993-11-15 Use of dimethylbenzofurans and dimethylbenzopyrans as 5-ht3 antagonists

Publications (2)

Publication Number Publication Date
LV10956A LV10956A (lv) 1995-12-20
LV10956B true LV10956B (en) 1996-10-20

Family

ID=25526607

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-95-184A LV10956B (en) 1992-11-20 1995-06-20 Use of dimethylbenzofurans and dimethylbenzopyrans as 5-ht3 antagonists

Country Status (31)

Country Link
US (2) US5674868A (OSRAM)
EP (1) EP0669919B1 (OSRAM)
JP (1) JP2830952B2 (OSRAM)
KR (1) KR0166661B1 (OSRAM)
AT (1) ATE176232T1 (OSRAM)
AU (1) AU680640B2 (OSRAM)
BG (1) BG62489B1 (OSRAM)
BR (1) BR9307477A (OSRAM)
CA (1) CA2149044C (OSRAM)
CZ (1) CZ287262B6 (OSRAM)
DE (1) DE69323322T2 (OSRAM)
DK (1) DK0669919T3 (OSRAM)
ES (1) ES2129615T3 (OSRAM)
FI (1) FI952458A7 (OSRAM)
GR (1) GR3029831T3 (OSRAM)
HU (2) HUT72740A (OSRAM)
IL (3) IL119273A0 (OSRAM)
LV (1) LV10956B (OSRAM)
MX (1) MX9307257A (OSRAM)
NO (2) NO307690B1 (OSRAM)
NZ (1) NZ257854A (OSRAM)
OA (1) OA10158A (OSRAM)
PL (1) PL176051B1 (OSRAM)
RO (1) RO115160B1 (OSRAM)
RU (1) RU2116072C1 (OSRAM)
SG (1) SG47488A1 (OSRAM)
SK (1) SK282378B6 (OSRAM)
TW (1) TW294595B (OSRAM)
UA (1) UA49792C2 (OSRAM)
WO (1) WO1994012494A1 (OSRAM)
ZA (1) ZA938676B (OSRAM)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5374637A (en) * 1989-03-22 1994-12-20 Janssen Pharmaceutica N.V. N-(3-hydroxy-4-piperidinyl)(dihydrobenzofuran, dihydro-2H-benzopyran or dihydrobenzodioxin)carboxamide derivatives
PT975327E (pt) * 1997-04-18 2003-11-28 Janssen Pharmaceutica Nv Uso de antagonistas de 5ht3 para estimular a lavagem intestinal
WO1999002496A1 (en) * 1997-07-11 1999-01-21 Janssen Pharmaceutica N.V. (+)-norcisapride useful for 5-ht3 and 5-ht4 mediated disorders
US6239122B1 (en) * 2000-01-05 2001-05-29 Joy Ann Steele Method of treatment of nausea, vomiting, and other disorders using estrogens
ATE440825T1 (de) * 2003-06-06 2009-09-15 Vertex Pharma Pyrimidin-derivate zur verwendung als modulatoren von atp-bindende kassette transportern
MXPA06005687A (es) 2003-11-20 2006-08-17 Janssen Pharmaceutica Nv 2-quinolinonas y 2-quinoxalinonas sustituidas con 6-alquenilo y 6-fenilalquilo como inhibidores de la poli(adenosin fosfato-ribosa)polimerasa.
EA011211B1 (ru) 2003-11-20 2009-02-27 Янссен Фармацевтика Н. В. 7-фенилалкилзамещённые 2-хинолиноны и 2-хиноксалиноны в качестве ингибиторов поли(адф-рибоза)полимеразы
AU2005259189B2 (en) 2004-06-30 2011-04-21 Janssen Pharmaceutica N.V. Phthalazine derivatives as PARP inhibitors
AU2005259192C1 (en) * 2004-06-30 2012-03-01 Janssen Pharmaceutica N.V. Substituted 2-alkyl quinazolinone derivatives as PARP inhibitors
SG154432A1 (en) 2004-06-30 2009-08-28 Janssen Pharmaceutica Nv Quinazolinedione derivatives as parp inhibitors
WO2008107478A1 (en) 2007-03-08 2008-09-12 Janssen Pharmaceutica Nv Quinolinone derivatives as parp and tank inhibitors
ES2448870T3 (es) 2007-10-26 2014-03-17 Janssen Pharmaceutica, N.V. Derivados de quinolina como inhibidores de PARP
JP5492183B2 (ja) 2008-03-27 2014-05-14 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｐａｒｐおよびチューブリン重合阻害剤としてのテトラヒドロフェナントリジノンおよびテトラヒドロシクロペンタキノリノン
EP2260026B1 (en) 2008-03-27 2011-06-22 Janssen Pharmaceutica, N.V. Quinazolinone derivatives as tubulin polymerization inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1183847A (en) * 1981-10-01 1985-03-12 Georges Van Daele N-(3-hydroxy-4-piperidinyl)benzamide derivatives
ZW12187A1 (en) * 1986-07-03 1989-02-01 Janssen Pharmaceutica Nv 4-(aroylamino)piperidinebutanamide derivatives
CA1317940C (en) * 1987-09-25 1993-05-18 Georges H. P. Van Daele Substituted n-(1-alkyl-3-hydroxy-4-piperidinyl)benzamides
US5374637A (en) * 1989-03-22 1994-12-20 Janssen Pharmaceutica N.V. N-(3-hydroxy-4-piperidinyl)(dihydrobenzofuran, dihydro-2H-benzopyran or dihydrobenzodioxin)carboxamide derivatives
US4914207A (en) * 1989-05-09 1990-04-03 Pfizer Inc. Arylthiazolylimidazoles
GB9005014D0 (en) * 1990-03-06 1990-05-02 Janssen Pharmaceutica Nv N.(4.piperidinyl)(dihydrobenzofuran or dihydro.2h.benzopyran)carboxamide derivatives

Also Published As

Publication number Publication date
HU9501476D0 (en) 1995-07-28
NO308530B1 (no) 2000-09-25
ES2129615T3 (es) 1999-06-16
AU5465994A (en) 1994-06-22
NO995762D0 (no) 1999-11-24
ZA938676B (en) 1995-05-19
NO307690B1 (no) 2000-05-15
SK67595A3 (en) 1995-11-08
DE69323322D1 (de) 1999-03-11
NO951980D0 (no) 1995-05-19
ATE176232T1 (de) 1999-02-15
DK0669919T3 (da) 1999-09-13
BR9307477A (pt) 1999-06-29
EP0669919A1 (en) 1995-09-06
BG99593A (en) 1995-12-29
IL107654A (en) 1998-01-04
IL119273A0 (en) 1996-12-05
EP0669919B1 (en) 1999-01-27
IL119273A (en) 2000-07-16
NO951980L (no) 1995-05-19
GR3029831T3 (en) 1999-06-30
IL107654A0 (en) 1994-02-27
SK282378B6 (sk) 2002-01-07
WO1994012494A1 (en) 1994-06-09
NO995762L (no) 1995-05-19
RU95113434A (ru) 1997-03-10
AU680640B2 (en) 1997-08-07
CZ125895A3 (en) 1995-10-18
PL176051B1 (pl) 1999-03-31
NZ257854A (en) 1997-04-24
RU2116072C1 (ru) 1998-07-27
HUT72740A (en) 1996-05-28
HU211546A9 (en) 1995-12-28
FI952458L (fi) 1995-05-19
OA10158A (en) 1996-12-18
LV10956A (lv) 1995-12-20
CA2149044C (en) 2007-04-03
FI952458A0 (fi) 1995-05-19
US5674868A (en) 1997-10-07
SG47488A1 (en) 1998-04-17
KR0166661B1 (ko) 1999-01-15
CZ287262B6 (en) 2000-10-11
CA2149044A1 (en) 1994-06-09
US5863923A (en) 1999-01-26
BG62489B1 (bg) 1999-12-30
JP2830952B2 (ja) 1998-12-02
FI952458A7 (fi) 1995-05-19
MX9307257A (es) 1994-05-31
RO115160B1 (ro) 1999-11-30
DE69323322T2 (de) 1999-09-09
UA49792C2 (uk) 2002-10-15
TW294595B (OSRAM) 1997-01-01
JPH08505840A (ja) 1996-06-25
PL309045A1 (en) 1995-09-18

Similar Documents

Publication Publication Date Title
US5652246A (en) Piperidine compounds
US5322844A (en) Alkoxy-4 (1H)-pyridone derivatives, processes for the preparation thereof, and pharmaceutical compositions containing them
EP0669919B1 (en) Use of dimethylbenzofurans and dimethylbenzopyrans as 5-ht3 antagonists
JP2830936B2 (ja) 置換ｎ−（１−アルキル−３−ヒドロキシ−４−ピペリジニル）ベンズアミド類
US8071651B2 (en) 5-amino-4-hydroxy-7-(imidazo [1,2-A] pyridin-6-ylmethyl)-8-methyl-nonamide derivatives and related compounds as renin inhibitors for the treatment of hypertension
ZA200302801B (en) Chimical compounds.
EP1870405A1 (en) Carbonylated (Aza)cyclohexanes as dopamine D3 receptor ligands
EP0727421B1 (en) Agents for improving sleep
JPH0730072B2 (ja) 置換３，４‐ジヒドロ‐２ｈ‐ベンゾピラン
US5026853A (en) 4-substituted-2(or 3)aminocarbonyl-1-piperazineacetamide
JP2009541251A (ja) 置換フェニルメタノン誘導体
FI90863B (fi) Analogiamenetelmä ripulinvastaisten 4-(bentsoyyliamino)piperidiinibutaaniamidijohdannaisten valmistamiseksi
CA2727669A1 (fr) Nouveaux derives de (piperazinyl ponte)-1-alcanone et leur utilisation comme inhibiteurs de p75
ZA200109706B (en) Ethanesulfonyl-piperidine derivatives.
NZ297312A (en) 1-[2-phenyl-4-(4-(3-hydroxythien-2-yl)piperidino)butanoyl]azepane derivatives
IE83401B1 (en) Agents for improving sleep